about
The relevance of piroxicam for the prevention and treatment of nonmelanoma skin cancer and its precursorsNovel transglutaminase 1 mutations in patients affected by lamellar ichthyosis.Sequential molecular analysis of circulating MCAM/MUC18 expression: a promising disease biomarker related to clinical outcome in melanoma.Immunologic biomarkers for clinical and therapeutic management of psoriasis.Pyoderma gangrenosum in refractory celiac disease: a case report.Knuckle pads, in an epidermal palmoplantar keratoderma patient with Keratin 9 R163W transgrediens expression.Severe erytrodermic psoriasis in child twins: from clinical-pathological diagnosis to treatment of choice through genetic analyses: two case reports.Tazarotene as alternative topical treatment for onychomycosis.Dermoscopy as an adjuvant tool for detecting skin leiomyomas in patient with uterine fibroids and cerebral cavernomas.Lack of efficacy of imiquimod in patients with basal cell carcinoma previously treated with rituximab for B cell lymphoma: two case reportsDermoscopic monitoring of efficacy of ingenol mebutate in the treatment of pigmented and non-pigmented basal cell carcinomas.Long-term use of a new topical formulation containing piroxicam 0.8% and sunscreen: efficacy and tolerability on actinic keratosis. A proof of concept study.Minimal residual disease in melanoma: circulating melanoma cells and predictive role of MCAM/MUC18/MelCAM/CD146.Peculiar clinical and dermoscopic remission pattern following imiquimod therapy of basal cell carcinoma in seborrhoeic areas of the face.Efficacy of a film-forming medical device containing sunscreen (50+) and piroxicam 0.8% in actinic keratosis and field cancerization: a multicenter, assessor-blinded, 3 month trial.The E3 ligase Itch knockout mice show hyperproliferation and wound healing alteration.Evidence of increased apoptosis and reduced proliferation in basal cell carcinomas treated with tazarotene.The use of high-dose immunoglobulin in the treatment of pyoderma gangrenosum.Adult female acne and associated risk factors: Results of a multicenter case-control study in Italy.Fungistatic activity of all-trans retinoic acid against Aspergillus fumigatus and Candida albicans.Loss of CRABP-II Characterizes Human Skin Poorly Differentiated Squamous Cell Carcinomas and Favors DMBA/TPA-Induced Carcinogenesis.New insight into the pathogenesis of nail psoriasis and overview of treatment strategies.Efficacy of ingenol mebutate gel for actinic keratosis in patients treated by thiazide diuretics.Superficial and nodular basal cell carcinomas treated with an immune response modifier: a report of seven patients.Imiquimod treatment of superficial and nodular basal cell carcinoma: 12-week open-label trial.Kaposi's sarcoma in a patient treated with imatinib mesylate for chronic myeloid leukemia.Topical treatment of actinic keratoses with piroxicam 1% gel: a preliminary open-label study utilizing a new clinical score.Progressive late-onset of cutaneous angiomatosis as possible sign of cerebral cavernous malformations.Bowenoid papulosis and invasive Bowen's disease: a multidisciplinary approach.IL-21 promotes skin recruitment of CD4(+) cells and drives IFN-γ-dependent epidermal hyperplasia.Type I lamellar ichthyosis improved by tazarotene 0.1% gel.CNS and cutaneous involvement in patients with chronic myeloid leukemia treated with imatinib in hematologic complete remission: two case reports.Actinic keratosis treated with an immune response modifier: a case report of six patients.Confocal reflectance microscopy in pityriasis rubra pilaris.Nodular morphea in a patient with Steinert disease.Dermatitis artefacta in sporadic sclerodermoid hepatitis C virus-associated porphyria cutanea tarda.Effect of calcipotriol on etanercept partial responder psoriasis vulgaris and psoriatic arthritis patients.Blood MUC-18/MCAM expression in patients with melanoma: a suitable marker of poor outcome.Relation between animal-type melanoma and reduced nuclear expression of glutathione S-transferase pi.Severe erytrodermic psoriasis and arthritis as clinical presentation of a CARD14-mediated psoriasis (CAMPS).
P50
Q26775913-589D0EE7-66D4-46C8-9A44-5F5BABBD4047Q30155199-4B3DA7CD-C636-4A93-820A-042664AC19EBQ33935453-3A2400C8-36C7-4626-AD70-719347D0426BQ34030644-1EE43496-9CDA-4D0E-BA5D-EFF5EE900B13Q34464588-EC7BCC36-F55A-4620-9335-5A0D26CF1C8AQ34910188-A3470D8B-28D5-42E4-B4D3-F07C6F43954CQ34990787-EADE6510-59F5-4022-B9B9-8F89385866C9Q35113266-C9610C87-4460-43D9-962D-7ADB11D1EE00Q35150350-CB7A43E2-53A5-4A26-87A3-4A0C67FD5EB8Q36679216-A66C8CD9-E076-4086-BACC-8FFBCB8BD5B4Q38793884-CA363B63-A209-4B50-B43D-7C25C576003AQ38885554-8172F80B-46D2-45FE-812F-98A2060FEEE9Q39172101-91676E75-5D4D-41F2-B4B4-B7D00681476DQ40029334-44E6F8F3-451E-481D-BF79-29513B2D5569Q40457310-9509B898-7066-46E1-A18C-886DE35BDD2BQ40548355-4B6D3914-0C27-428C-AFC0-1FB82C2E5545Q40564155-4A08DB44-204B-48A7-8061-93F9AFA31785Q40576956-0A0B486D-9D3D-4DE9-B6F4-5786E0F434E6Q40614893-8F10E521-D998-4ABB-93B2-FC05049FF9BEQ40666647-CF843524-4C52-4EF7-B228-CF311C97ED1FQ40870211-2165D12F-EDAB-4EDE-B893-0470C16AAE27Q41633453-107A0EC2-5A74-4E3B-88D3-3772F96A7EBEQ42142318-91C79568-ECD0-455C-B32E-EB5DF919FB20Q42452780-24FB507B-9DE5-4488-9A02-B06869404E34Q42477168-430300A5-1C11-427D-A90B-EAA1AA1967D6Q43181664-FECD228A-3B5C-4EB2-BDA2-EC4A8FFDEE5EQ43225939-1F9A6D84-0FB6-4FF6-863B-3BA01DC8F241Q43424464-8571D4EF-15FA-4D72-856F-97FC1FA52D3AQ43733543-157FA353-9A97-4507-8EE8-98679335AEB7Q43923044-238BCAC2-E3ED-46E7-94B7-CED74CAE2BBAQ44489051-273CD82E-BE7D-4E92-89D7-FB6C090046A2Q44654361-694CBBC2-87A9-4859-B0C7-1C280FAF3A88Q44655284-3A37F35C-66F6-420F-B5B8-8EFC928F1BABQ44691845-3C4D6EDE-4A67-499A-BE6F-E11AA862ED46Q45067170-25437CB8-357F-4521-B557-8B119FEF5852Q45386659-EBCF005B-DE7D-41B1-9EEB-1858D845B770Q45991209-311A3F71-26CD-434A-808C-EA059598A619Q46095671-834AB044-0887-4AE1-BA05-7CCB338127ADQ46157323-51210840-8D18-4D3F-A5D2-72E83FDA8577Q46271781-F7FE5C11-9D7A-4B4F-8DEB-75B26ECE6E26
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Elena Campione
@ast
Elena Campione
@en
Elena Campione
@es
Elena Campione
@nl
Elena Campione
@sl
type
label
Elena Campione
@ast
Elena Campione
@en
Elena Campione
@es
Elena Campione
@nl
Elena Campione
@sl
prefLabel
Elena Campione
@ast
Elena Campione
@en
Elena Campione
@es
Elena Campione
@nl
Elena Campione
@sl
P106
P21
P31
P496
0000-0001-7447-6798